Strategic partnerships Altis Labs collaborates with leading biopharma and cancer centers, indicating strong potential for expanded AI-driven trial design collaborations, real-world data partnerships, and joint development initiatives.

IPRO clinical value IPRO imaging-based prognostication models are already used to optimize trial design and patient selection, suggesting opportunities to upsell regulatory-grade prognostic tools to ongoing and upcoming Phase 2/3 programs.

CT imaging analytics Recent work on CT scan analysis and multifaceted biomarker quantification (tumors, muscle, fat, cardiovascular health) opens doors for cross-modality integrations with existing imaging workflows in multi-center trials.

Awards and credibility Recent Maple Leaf Award and conference showcases at CBCS and ASCO boost credibility, easing outreach to potential customers and procurement teams seeking validated AI imaging solutions.

Growth signals Revenue range and early-stage funding, combined with a growing enterprise client base, indicate readiness for scale-focused offerings, including external control arms, rwDTs, and AI-enabled trial optimization products.